Medtronic plc. (MDT)
|Net Income (ttm)||4.32B|
|Ex-Dividend Date||Sep 22, 2022|
|Day's Range||77.3 - 78.92|
|52-Week Range||75.83 - 114.31|
|Price Target||95.77 (+21.9%)|
|Earnings Date||Nov 22, 2022|
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accesso... [Read more]
In 2022, Medtronic plc.'s revenue was $31.69 billion, an increase of 5.21% compared to the previous year's $30.12 billion. Earnings were $5.04 billion, an increase of 39.74%.Financial Statements
According to 34 analysts, the average rating for MDT stock is "Buy." The 12-month stock price forecast is 95.77, which is an increase of 21.86% from the latest price.
Medtronic PLC ( MDT , Financial) is an attractive stock for investors looking for solid and profitable options. The broad portfolio of medical devices, medications and services has been the driving forc...
DUBLIN , Dec. 8, 2022 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary sh...
Medtronic completes enrollment in pivotal trial evaluating first-of-its-kind pulsed field ablation catheter for patie...
SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN , Dec. 5, 2022 /PRNewswire/ -- Medtro...
With the holiday season upon us, investors may want to focus largely on dividend stocks to buy. While growth-oriented names provide the most excitement, market participants must acknowledge reality.
The lowest yield on this list is 2.7%.
The recent fall can be attributed to the Q2FY23 results the company reported yesterday, with revenue falling below and earnings above our estimates.
DUBLIN , Nov. 23, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5th annual HealthCONx conference on Tue...
Supply-chain and demand challenges pressure the Dublin-based company's latest quarterly results.
Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.
Medtronic (MDT) delivered earnings and revenue surprises of 1.56% and 1.72%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic reported mixed earnings and lighter-than-expected organic sales growth, leading MDT stock to tumble. The post Medical Behemoth Medtronic Crumbles After Missing Its Own Guidance appeared first ...
The medical device maker misses fiscal second-quarter sales expectations and lowers its earnings guidance for the year.
Shares of Medtronic PLC MDT, +1.22% dropped 2.4% in premarket trading Tuesday, after the medical devices maker reported fiscal second-quarter profit that topped expectations but revenue that missed and ...
Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Medtronic...
These stocks offer attractive yields now, and investors can look forward to lots of payout raises.
These impressive businesses seem to have plenty of room for further growth.
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Medtronic (NYSE: MDT) is scheduled to report its fiscal 2023 second-quarter results on Tuesday, November 22. We expect Medtronic to post revenues and earnings in line with the street estimates.
DUBLIN , Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 202...
Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.
Annual costs savings of insulin of up to 25% and plastic waste reduction of up to 50% with Medtronic Extended infusion set DUBLIN , Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leade...